Brawn Biotech has informed that pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the meeting of Board of Directors of the Company is scheduled to be held on Thursday, 5th November, 2026 to consider and approve the un-audited financial results of the Company for the quarter ended September 30, 2026. As intimated in letter dated September 28, 2026 for the purpose of closure of Trading Window and as per the Company’s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for the dealing in the securities of the Company shall remain closed till 16th November, 2026 and accordingly shall reopen on 17th November 2026.
The above information is a part of company’s filings submitted to BSE.